NSCLC
Conditions
Keywords
NSCLC；, perioperative treatment
Brief summary
This is an observational study evaluating the clinical characteristics, treatment patterns, and clinical outcomes of perioperative NSCLC patients receiving different treatment strategies. According to the inclusion and exclusion criteria, perioperative NSCLC patients admitted to the study center from January 1, 2020, to one year after the study initiation will be retrospectively screened and collected.
Interventions
None listed
Sponsors
Shanghai Chest Hospital
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* Stage I-III NSCLC patients confirmed by histological or cytological examination based on the 8th edition of the AJCC staging system. * Patients who have undergone radical lung cancer surgery. * Patients who have received neoadjuvant treatment before radical lung cancer surgery, including chemotherapy, targeted therapy, or immunotherapy both alone or combined.
Exclusion criteria
* Patients with other previous malignancies, except those who achieved complete remission at least two years before radical lung cancer surgery and did not require additional treatment. * Patients with incomplete key baseline and treatment information，including clinical stage, pathological type, neoadjuvant treatment, pathological response, imaging response after neoadjuvant. * Patients included in anti-tumor drug intervention or unblinded clinical trials, in which the treatment being administered is unknown. * Prior surgery, radiotherapy or systemic therapy for NSCLC, including radiofrequency ablation, etc.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| event-free survival | From date of diagnosis until the date of first documented progression, recurrence or date of death from any cause, whichever came first, assessed up to 36 months | the time from randomization to any progression of disease precluding surgery, progression or recurrence of disease after surgery, progression of disease in the absence of surgery, or death from any cause; |
| overall survival | From date of diagnosis until the date of death from any cause, whichever came first, assessed up to 60 months | from diagnosis to death |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| R0 resection rate | usually 1 week after surgery | margin negative resection |
| major pathological response | usually 1 week after surgery | viable tumor cell less than 10% |
| p-CR | usually 1 week after surgery | no viable tumor cells was observed |
Countries
China
Outcome results
None listed